Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — Investor Presentation (September 2021)
16 slides from Mlp Saglik Hizmetleri As Class B's investor presentation, Sep 16, 2021
Slide 1: MLP Care Investor Presentation
MLP Care Investor Presentation Unlu&Co Meeting With Turkish Funds September 16, 2021
Slide 2: At a Glance: MLP Care Q2 2021 Financial Highlights
At a Glance: MLP Care Q2 2021 Financial Highlights (w/o fx impact) Adj. EBITDA Revenue Low base of last year supported both domestic and foreign medical revenue TL 1,331 m TL 320 m 75% Growth 63% Growth growth H1 2021: H1 2021: 46% Growth 53% Growth Net profit improved mainly due to strong ope
Slide 3: Strong Revenue Growth Supported by Low Base
Strong Revenue Growth Supported by Low Base Revenue (TLm) 46.3% 2,542 75.3% 1,738 1,331 759 Q2 2020 Q2 2021 H1 2020 H1 2021 Denotes growth of Revenue vs. the same period of the last year 3
Slide 4: Strong Revenue Growth Supported by Low Base
Strong Revenue Growth Supported by Low Base Domestic Patient Medical Tourism Ancillary Business Revenue Revenue 50.5% 87.1% (48.5%) 72.2% 308.5% 2,225 (42.7%) 253 64 1,157 144 30 Q2 2021 H1 2021 Q2 2021 H1 2021 Q2 2021 H1 2021 Domestic Revenue q-o-q Growth Accelerated Recovery of Decrease in Laborat
Slide 5: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 62.3% 43.4% 42.2% 34.4% 20.1% 9.1% 318 234 111 898 1,327 84 553 926 H1 2020 Volume & Mix Price H1 2021 H1 2020 Volume & Mix Price H1 2021 Average Revenue Per Visit (ARPV) Average Revenue Per Protocol (ARPP) 47
Slide 6: EBITDA Growth on the Back of Strong Revenue Recovery
EBITDA Growth on the Back of Strong Revenue Recovery EBITDA (TLm) EBITDA2 (TLm) (w/o fx impact) 48.8% 52.7% 676 633 50.6% 454 62.8% 414 330 320 219 196 Q2 2020 1 Q2 2021 1 H1 2020 1 H1 2021 1 Q2 2020 2 Q2 2021 2 H1 2020 2 H1 2021 2 1 Adj. EBITDA: EBITDA TFRS adjustments that have no cash impact on r
Slide 7: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin Adj. EBITDA Margin 26.1% 26.6% Material costs as a % of revenue declined in H1 2021 1.0% 0.8% due to decrease in the share of laboratory business which
Slide 8: Strong Net Profit Improvement
Strong Net Profit Improvement Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 344.5% 435.8% 174 147 95 82 (22) 39 (23) 27 Q2 2020 Q2 2021 H1 2020 H1 2021 Q2 2020 Q2 2021 H1 2020 H1 2021 Denotes growth of Net Profit and Net Profit Allocated to Equity Holders of the Parent
Slide 9: FX Exposure in Net Debt Eliminated in February 2021
FX Exposure in Net Debt Eliminated in February 2021 FX BASED NET DEBT 1 (in EUR m) GROSS DEBT PERCENTAGE 2020 H1 2021 EUR30m EUR32m EUR27m equivalent of equivalent of equivalent of Cash Balance 580mTL Cash Balance 375mTL FX Cash FX Cash FX Cash Balance Balance Balance 15% 21% 85% 79% 65 51 Net Debt
Slide 10: Improved Free Cash Flow and Operating Cash Flow
Improved Free Cash Flow and Operating Cash Flow Maintenance Capex (TLm) Total Capex (TLm) OCF/ EBITDA FCF/ EBITDA 101.4% 76.4% 2.1% 6.7% 1.9% 78.9% 685 66.4% 3.3% 169 516 53 359 33 302 57 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 H1 2020 H1 2021 % of Revenue % of Revenue % of EBITDA % of EBITD
Slide 11: Appendix
M LPCA RE MEDICALPARK | VW nospitac 11
Slide 12: Strong Revenue Growth Supported by Low Base
Strong Revenue Growth Supported by Low Base H1 2021 (48%) 87% Revenue from SSI was up by 26% in Q2 2021 3% (SSI Insurance allows for a wide addressable market, 10% which is c.98% of the total population) 29% 26% Self pay was up by 71% in Q2 2021 Revenue from PMI, Top-up & Contracted Institutio
Slide 13: # of People with Top-up Insurance Over 2 million
# of People with Top-up Insurance Over 2 million # of People with Insurance in Turkey (in thousand) 2,399 2,022 4,421 2,282 1,501 3,784 Growth (H1 2020 – H1 2021) 5.1% 34.7% 16.8% PMI Top-up PMI+Top-up # of People with Top-up Insurance in Turkey (in thousand) 06.2021; 2,022 06.2020; 1,501 Average LT
Slide 14: Significant Growth Potential of FMT Revenue
Significant Growth Potential of FMT Revenue Medical Tourism Revenue (USD m) TOP 10 FMT Revenue % by Department in H1 2021 12.2% 32.7% (36.7%) 12% 10% 10% 37.4% 77 7% 7% 68 53.9% 5% 4% 3% 3% 3% 52 49 General Surgery Pulmonary Hematology Orthopedics Hematology Cardiology Diseases Oncology Brain and Ne
Slide 15: Liv Hospital Brand Expands in İstanbul
Liv Hospital Brand Expands in İstanbul Map of Istanbul Liv Hospital VadIstanbul Hospitals with Medical Park Brand Location: Sarıyer / Istanbul Hospitals with Liv Hospital Brand Opening Date: May 2021 Key Statistics 35k sqm 125 bed capacity 76 policlinic rooms 7 operating rooms MLP Care hos
Slide 16: Disclaimer / IR Contact
Disclaimer This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently available data. Act